AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-08. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
GeneReviews/NCBI/NIH/UW entry on Early-Onset Familial Alzheimer Disease Amyloid+Protein+Precursor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Entrez Gene: APP amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease) Human APP genome location and APP gene details page in the UCSC Genome Browser.
== Signs and symptoms == Symptoms of cold agglutinin disease (CAD) are often triggered or made worse by cold temperatures or a viral infection. Therefore, symptoms generally are worse during winter months. Symptoms may arise suddenly leading to abrupt onset of severe anemia and hemoglobinuria or develop more gradually and insidiously in the background without patient's consciousness and precaution. Most people with CAD have symptoms of hemolytic anemia (destruction of red blood cells, causing low levels of red blood cells). However, the number of symptoms and severity of symptoms may depend on how severe the anemia is. Signs and symptoms of hemolytic anemia may include:
Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting factor (MIF), is a protein that in humans is encoded by the AMH gene. AMH is a glycoprotein hormone that belongs to the transforming growth factor beta (TGF-β) superfamily, which also includes inhibin and activin. These hormones play important roles in cell growth and development, sex differentiation in males, and the formation of ovarian follicles. In humans, the AMH gene is located on chromosome 19p13.3, while its receptor is encoded by the AMHR2 gene on chromosome 12. In male embryos, AMH is switched on by the SOX9 gene in Sertoli cells of the developing testes. AMH acts to block the development of the Müllerian ducts (also called paramesonephric ducts), which would otherwise form the uterus, fallopian tubes, and upper part of the vagina. This allows male reproductive organs to develop. The production of AMH during this specific window of fetal development is tightly regulated by other factors, including the nuclear receptor SF-1, GATA transcription factors, the sex-determining gene DAX1, and follicle-stimulating hormone (FSH). Mutations in the AMH gene or its receptor (type II AMH receptor) can result in the persistence of Müllerian duct structures in otherwise normally developed males. In females, AMH is produced by granulosa cells in developing ovarian follicles, especially in the early (preantral and small antral) stages. AMH is present in the ovaries until menopause.
Sources: en.wikipedia.org
In 2019, the FDA issued a drug safety warning about serious breathing difficulties in patients using pregabalin or gabapentin, particularly when combined with opioids or other CNS depressants. A 2022 meta-analysis found that combination therapy with opioids and gabapentinoids could be associated with an increased risk of CNS depression and mortality, and concluded that combination therapy with these medications requires close clinical monitoring. Combined use of pregabalin and alcohol produces additive impairment of cognitive and psychomotor function, as both substances act as central nervous system depressants. The pregabalin prescribing information advises against alcohol consumption during treatment, noting that the CNS depressant effects of the two substances compound one another. The combination of pregabalin and benzodiazepines produces additive CNS and respiratory depression, with pregabalin pharmacodynamically augmenting benzodiazepine sedation. A 2020 study published in the British Journal of Anaesthesia examining gabapentinoid prescribing trends in Scotland found that among recurrent gabapentinoid users, benzodiazepines were co-prescribed in 26.8% of cases, opioids in 49.9%, and both in a further 17.1%, and that the age-standardised death rate among those prescribed gabapentinoids was double that of the general Scottish population. The prescribing information for pregabalin advises monitoring for respiratory depression and sedation when co-prescribing with benzodiazepines.
==== Nonhospitalized outpatients ==== In January 2022, a study indicated that nonhospitalized people who were at high risk for COVID‑19 progression had an 87% lower risk of hospitalization or death after a 3-day course of intravenous remdesivir.
The sector is composed of both "dedicated" AI companies, those for which AI is the primary revenue source, and "diversified" companies, which offer AI products and services as part of a broader commercial offering. In 2024, 56% of identified firms were dedicated and 44% were diversified, with the share of diversified companies continuing to grow year-on-year, reflecting the increasing integration of AI across the wider economy. The vast majority (95%) of all identified AI companies are small and medium-sized enterprises (SMEs), with micro-businesses (fewer than 10 employees) accounting for 70% of the sector.
==== Other countries ==== Usually, the availability of oxandrolone is quite limited. It is no longer available in Europe. Oxandrolone is available in some less-regulated markets in Asia such as Malaysia and in Mexico. Historically, oxandrolone has been marketed in Argentina, Australia, Brazil, France, Italy, Japan, and Spain, but it appears to no longer be available in these countries.
Sources: en.wikipedia.org
=== Refugees === On January 20, 2025, Trump signed the executive order named "Securing Our Borders". This order suspends the Uniting for Ukraine parole program, and no new applications from Ukrainian refugees with relatives in the United States are being accepted. On May 12, 59 white South African refugees arrived from South Africa. The Trump administration has been criticized for fast-tracking their applications while pausing other refugee programs. The Trump administration slowed the entry of Afghan refugees into the U.S., including persons who had fought on the U.S. side against the Taliban. A leader of an American veterans group said, "these pilots risked everything for America. Their lives are now on the line because of our failure to follow through on our promises." On May 12, Department of Homeland Security Secretary Noem announced that TPS, or temporary protected status, for Afghan refugees would be ended in 60 days, which is the shortest time period permitted by United States law. This decision cited improved conditions in Afghanistan. The Hill reports that the UN high commissioner for refugees has stated that the situation in Afghanistan has not improved, with a report stating "The large-scale returns are putting even greater pressure on already stretched humanitarian resources." On the other hand, Secretary Noem has pointed to an increase in tourists from China and a drop in the number of Afghans needing assistance from 29 million to 24 million.
Microorganisms may also be identified using automated systems, such as instruments that perform panels of biochemical tests, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), in which microbial proteins are ionized and characterized on the basis of their mass-to-charge ratios; each microbial species exhibits a characteristic pattern of proteins when analyzed through mass spectrometry. Because bloodstream infections can be life-threatening, timely diagnosis and treatment is critical, and to this end several rapid identification methods have been developed. MALDI-TOF can be used to identify organisms directly from positive blood culture bottles after separation and concentration procedures, or from preliminary growth on the agar plate within a few hours of subculturing. Genetic methods such as polymerase chain reaction (PCR) and microarrays can identify microorganisms by detection of DNA sequences specific to certain species in blood culture samples. Several systems designed for the identification of common blood culture pathogens are commercially available. Some biochemical and immunologic tests can be performed directly on positive blood cultures, such as the tube coagulase test for identification of S. aureus or latex agglutination tests for Streptococcus pneumoniae, and unlike PCR and MALDI-TOF, these methods may be practical for laboratories in low and middle income countries.
This differential equation is the classic equation of motion of a charged particle in a vacuum. Together with the particle's initial conditions, it determines the particle's motion in space and time. It immediately reveals that two particles with the same m/Q ratio behave in the same way. This is why the mass-to-charge ratio is an important physical quantity in those scientific fields where charged particles interact with magnetic or electric fields.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.